Variants in GLP‑1 and GIP receptor genes partly determine weight loss and nausea risk on GLP‑1 drugs, signaling a shift from one‑size‑fits‑all treatment.

Clinical genome sequencing now delivers genetic diagnoses for about 1 in 4 suspected rare disease patients, guiding targeted care and shaping newborn screening worldwide.

Quarterly RNA drug plozasiran turns off a liver gene, sharply lowering life‑threatening pancreatitis attacks in a rare genetic disorder.

Serially cloned mice hit a genetic “dead end” by generation 58, underscoring that sex evolved for variation, purging harmful mutations and keeping lineages viable.

Programmable cell‑like particles seek out drug‑resistant bacteria, inject lethal payloads, and spare beneficial microbes.

Healthcare initiatives being proposed like Patients’ Bill of Rights offer a roadmap for Democrats’ priorities, with midterms looming and a presidential election in 2028.

Trump administration is considering auto-enrollment for Medicare enrollees in Medicare Advantage. This suggests a preference for the program over traditional Medicare.

A lymph node–targeted delivery platform releases antibody therapy only in tumor-like conditions, strengthening immune attack on metastatic cancer.

Cross-species research shows that RNA splicing patterns, not just gene activity, track maximum lifespan in mammals, revealing a new axis of longevity control.

New structural insights reveal a clever new use of antibodies to treat and possibly prevent infections by on the of the world’s deadliest viruses.